




RealRate

PHARMACEUTICAL 2018

Adamas Pharmaceuticals Inc
Rank 240 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Adamas Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamas Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Adamas Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 153% points.

The company's Economic Capital Ratio, given in the ranking table, is 175%, being 76% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	179,175
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,607
Liabilities, Non-Current	103,443
Other Assets	3,869
Other Compr. Net Income	26
Other Expenses	1,581
Other Liabilities	0
Other Net Income	0
Other Revenues	571
Property and Equipment	3,132
Research and Development	27,168
Selling, General and Administrative Expense	61,312

Output Variable	Value in 1000 USD
Assets	186,176
Liabilities	120,050
Expenses	90,061
Revenues	571
Stockholders Equity	66,126
Net Income	-89,490
Comprehensive Net Income	-89,477
BaseVar	198,442
ECR before LimitedLiability	36%
Economic Capital Ratio	175%